La Jolla Performance

LJPC -- USA Stock  

Quarterly Earning Report: October 23, 2019  

The company owns Beta (Systematic Risk) of 0.3898 which conveys that as returns on market increase, La Jolla returns are expected to increase less than the market. However during bear market, the loss on holding La Jolla will be expected to be smaller as well. Even though it is essential to pay attention to La Jolla Pharmaceutical existing price patterns, it is always good to be careful when utilizing equity price patterns. Macroaxis approach towards estimating future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. La Jolla exposes twenty-one different technical indicators which can help you to evaluate its performance. La Jolla Pharmaceutical has expected return of -0.0611%. Please be advised to verify La Jolla Pharmaceutical Company Jensen Alpha, and the relationship between Coefficient Of Variation and Potential Upside to decide if La Jolla Pharmaceutical past performance will be repeated at some future date.

Risk-Adjusted Performance

Over the last 30 days La Jolla Pharmaceutical Company has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, La Jolla is not utilizing all of its potentials. The prevalent stock price disturbance, may contribute to short term losses for the investors.
Quick Ratio5.70
Fifty Two Week Low5.01
Target High Price27.00
Fifty Two Week High18.44
Target Low Price7.00
Horizon     30 Days    Login   to change

La Jolla Pharmaceutical Relative Risk vs. Return Landscape

If you would invest  895.00  in La Jolla Pharmaceutical Company on September 14, 2019 and sell it today you would lose (55.00)  from holding La Jolla Pharmaceutical Company or give up 6.15% of portfolio value over 30 days. La Jolla Pharmaceutical Company is currently does not generate positive expected returns and assumes 2.7807% risk (volatility on return distribution) over the 30 days horizon. In different words, 24% of equities are less volatile than La Jolla and 99% of traded equity instruments are projected to make higher returns than the company over the 30 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 30 days, La Jolla is expected to under-perform the market. In addition to that, the company is 2.84 times more volatile than its market benchmark. It trades about -0.02 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.03 per unit of volatility.

La Jolla Market Risk Analysis

Sharpe Ratio = -0.022
Good Returns
Average Returns
Small Returns
Negative ReturnsLJPC

La Jolla Relative Performance Indicators

Estimated Market Risk
  actual daily
 24 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average La Jolla is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of La Jolla by adding it to a well-diversified portfolio.

La Jolla Alerts

Equity Alerts and Improvement Suggestions

La Jolla generates negative expected return over the last 30 days
La Jolla has high likelihood to experience some financial distress in the next 2 years
The company reported previous year revenue of 17.75 M. Net Loss for the year was (158.26 M) with loss before overhead, payroll, taxes, and interest of (106.49 M).
LA JOLLA PHARMA currently holds about 123.45 M in cash with (118.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.55.
Over 105.0% of the company shares are owned by institutional investors
Latest headline from Current Alteration La Jolla Pharmaceutical Company, - Ws News Alerts
Please see also Stocks Correlation. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.